The Clinical Pharmacology and Analyfical Chemistry (CPAC) Core contains clinical pharmacology expertise with a CLIA-certified laboratory to support clinical and preclinical HIV/AIDS research among CFAR invesfigators at UNC, FHl, and RTI. Since the CPAC Core is the only one of its kind within the CFAR system, it also supports a growing number of invesfigators in other CFARs across the country. The CPAC Core consists of experienced scientists who provide a high level of expertise in trial design, development and validation of analytical methods in complex biological matrices to accurately quantify drug exposure, and interpretation of preclinical and clinical pharmacology data. The CPAC Core also provides leadership in HIV prevention strategies, women's health issues, and international pharmacology, and trains domestic and international investigators in pharmacologic and analytic methods.
A major feature of controlling the HIV epidemic is the complex interplay between drug exposure and response in treatment, prevention, and cure. This is evidenced in the extensive preclinical and early clinical dose-response investigations during drug development. Optimizing effective therapy in any of these areas of the epidemic requires extensive knowledge of exposure targets and pharmacokinefics in multiple body compartments to chose the best doses, dosing frequencies, and drug combinations for efficacy. The CPAC Core provides the necessary resources for CFAR users to optimize their preclinical and clinical research approach.
|Cottrell, Mackenzie L; Yang, Kuo H; Prince, Heather M A et al. (2016) A Translational Pharmacology Approach to Predicting Outcomes of Preexposure Prophylaxis Against HIV in Men and Women Using Tenofovir Disoproxil Fumarate With or Without Emtricitabine. J Infect Dis 214:55-64|
|Sin, Sang-Hoon; Kang, Sun Ah; Kim, Yongbaek et al. (2016) Kaposi's Sarcoma-Associated Herpesvirus Latency Locus Compensates for Interleukin-6 in Initial B Cell Activation. J Virol 90:2150-4|
|Rutstein, S E; Golin, C E; Wheeler, S B et al. (2016) On the front line of HIV virological monitoring: barriers and facilitators from a provider perspective in resource-limited settings. AIDS Care 28:1-10|
|Davis, Nicole L; Miller, William C; Hudgens, Michael G et al. (2016) Maternal and Breastmilk Viral Load: Impacts of Adherence on Peripartum HIV Infections Averted-The Breastfeeding, Antiretrovirals, and Nutrition Study. J Acquir Immune Defic Syndr 73:572-580|
|Davis, Alissa; Meyerson, Beth E; Aghaulor, Blessing et al. (2016) Barriers to health service access among female migrant Ugandan sex workers in Guangzhou, China. Int J Equity Health 15:170|
|Chen, J; Malone, S; Prince, H M A et al. (2016) Model-Based Analysis of Unbound Lopinavir Pharmacokinetics in HIV-Infected Pregnant Women Supports Standard Dosing in the Third Trimester. CPT Pharmacometrics Syst Pharmacol 5:147-57|
|Cottrell, Mackenzie L; Prince, Heather M A; Allmon, Andrew et al. (2016) Cervicovaginal and Rectal Fluid as a Surrogate Marker of Antiretroviral Tissue Concentration: Implications for Clinical Trial Design. J Acquir Immune Defic Syndr 72:498-506|
|Lancaster, Kathryn E; Go, Vivian F; Lungu, Thandie et al. (2016) Substance use and HIV infection awareness among HIV-infected female sex workers in Lilongwe, Malawi. Int J Drug Policy 30:124-31|
|O'Donnell, Julie K; Gaynes, Bradley N; Cole, Stephen R et al. (2016) Ongoing life stressors and suicidal ideation among HIV-infected adults with depression. J Affect Disord 190:322-8|
|Barlow-Mosha, Linda; Angelidou, Konstantia; Lindsey, Jane et al. (2016) Nevirapine- Versus Lopinavir/Ritonavir-Based Antiretroviral Therapy in HIV-Infected Infants and Young Children: Long-term Follow-up of the IMPAACT P1060 Randomized Trial. Clin Infect Dis 63:1113-21|
Showing the most recent 10 out of 1330 publications